Korissa Gillespie, APRN
Acute Care · Oklahoma City, OKNPI 1376137141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 154 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$634
- Pfizer$422
- AbbVie$376
- Neurocrine Biosciences, Inc.$246
- Merz Pharmaceuticals, LLC$191
- UCB, Inc.$160
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $634 |
| Pfizer | 32 | $422 |
| AbbVie | 14 | $376 |
| Neurocrine Biosciences, Inc. | 13 | $246 |
| Merz Pharmaceuticals, LLC | 8 | $191 |
| UCB, Inc. | 5 | $160 |
| Argenx US, Inc. | 7 | $150 |
| AstraZeneca | 7 | $134 |
| Teva Pharmaceuticals USA, Inc. | 6 | $122 |
| Lundbeck LLC | 6 | $111 |
| Lilly USA, LLC | 4 | $67 |
| SK Life Science, Inc. | 3 | $62 |
| Biogen | 3 | $60 |
| Eisai Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $45 |
| EMD Serono, Inc. | 2 | $38 |
| Tanabe Pharma America, Inc. | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Amgen | 1 | $25 |
| CSL Behring | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,096 in reported general payments places this provider in the 80th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 88 | $152,679 |
| Emgality PenGalcanezumab-Gnlm | 175 | $138,554 |
| UbrelvyUbrogepant | 63 | $77,965 |
| Aimovig AutoinjectorErenumab-Aooe | 88 | $64,237 |
| QuliptaAtogepant | 22 | $24,892 |
| ReyvowLasmiditan Succinate | 11 | $8,132 |
| Lacosamide | 33 | $6,721 |
| Carbamazepine ErCarbamazepine | 20 | $3,062 |
| RizatriptanRizatriptan Benzoate | 124 | $2,261 |
| Sumatriptan | 11 | $1,338 |
| Oxcarbazepine | 13 | $942 |
| Propranolol Hcl | 96 | $800 |
| Pregabalin | 17 | $689 |
| Levetiracetam | 52 | $626 |
| Topiramate | 57 | $543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $422 | $152,67988 claims |
| AbbVieUbrelvy, Qulipta | $376 | $102,85685 claims |
| Lilly USA, LLCReyvow | $67 | $8,13211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 acute care providers in Oklahoma.
Other acute care in Oklahoma City
- Karen GregoryOklahoma City$68K
- Katrina PyleOklahoma City$13K
- Deborah PeterOklahoma City$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
- Scottie SmithOklahoma City$8K
- Maria BacaOklahoma City$7K
- Janet FundaroOklahoma City$7K
- Silvia Olivares MendozaOklahoma City$6K
- Bonnie RenfroOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.